FindTrial
Sign In

Antibody response to SARS-CoV-2 vaccination in patients with liver disease

Antibody response to SARS-CoV-2 vaccination in patients with liver disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065461
Enrollment
Unknown
Registered
2022-11-04
Start date
2022-11-10
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver disease

Interventions

LD patients group:N
control group:N

Sponsors

Shandong Provincial Hospital Affiliated to Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with liver disease; 2. Patients and healthy controls who had received the SARS-CoV-2 vaccines.

Exclusion criteria

Exclusion criteria: Participants who were pregnant, less than 18 years old, with malignant tumors, with known prior COVID-19 infection, history of receiving systemic immunosuppressants were excluded.

Design outcomes

Primary

MeasureTime frame
Neutralizing ntibody concentration;Anti-spike IgG antibody concentration;—

Countries

China

Contacts

Public ContactQiang Zhu

Shandong Provincial Hospital Affiliated to Shandong First Medical University

zhuqiang@sdu.edu.cn+86 15168887780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026